aid: eqrx
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/eqrx.png
name: EQRx
description: >-
  EQRx was a biopharmaceutical company based in Cambridge, Massachusetts, founded in 2020
  by Alexis Borisy with a mission to develop and deliver innovative, patent-protected
  medicines at radically lower prices. The company went public in 2021 through a SPAC merger
  with CM Life Sciences III and built an oncology and immunology pipeline anchored by in-licensed
  candidates such as aumolertinib and sugemalimab. In 2023 EQRx wound down its drug-development
  programs and was acquired by Revolution Medicines in an all-stock transaction. It was surfaced
  in the API Evangelist network as a portfolio-company lead (backed by a16z and GV); it never
  operated a public developer platform or API, and its web presence is no longer live.
url: https://raw.githubusercontent.com/api-evangelist/eqrx/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- a16z
- gv
x-tier: stub
x-tier-reason: portfolio-lead
x-status: defunct
x-status-note: Acquired by Revolution Medicines (2023); drug-development wound down; no live developer surface.
x-headquarters: Cambridge, Massachusetts, United States
x-founded: '2020'
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-19'
tags:
- Company
- Biopharmaceutical
- Pharmaceuticals
- Biotechnology
- Oncology
- Drug Development
- Life Sciences
- Healthcare
common:
- type: DomainSecurity
  url: security/eqrx-domain-security.yml
- type: Website
  url: https://eqrx.com
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence